

- Absolute cell counts, 28
- Accuracy
 definition, 95
 quality control (QC) and, 73
 validation protocol and, 77–79
- Acid citrate dextrose (ECD), hematolymphoid neoplasia analysis and, 119–120
- Acid elution methods for maternal antibodies, 297
- Acquired immunodeficiency syndrome (AIDS). *See also* Human immunodeficiency virus (HIV)
 HIV history and, 260
 monoclonal surface marker assays and, 4
- ACS, 56
- Activated T-cell rosette assay, T/B lymphocytes and, 5
- Acute leukemias of ambiguous lineage, 203–207
- Acute lymphoblastic leukemia (ALL)
 advantages of flow cytometry in diagnosis of, 167
 antibody selection/combinations and, 169, 172–173
 differential diagnostic issues
 abnormalities of antigen expression, 183
 maturing B-cell precursor hyperplasia vs precursor B-cell, 180–185
 precursor T-lymphoblastic lymphoma/leukemia vs peripheral T-cell lymphoma, 190, 194
 precursor T-lymphoblastic lymphoma/leukemia vs thymoma, 185–188
 sIg+ precursor B-cell ALL vs mature non-Hodgkin lymphoma, 188–189
 four-color antibody combinations for, 172
 gating strategies for, 168–169
 immunologic subtypes of, 176
 immunophenotypic/genotypic correlations
 MLL gene rearrangements, 179
 t(1;19), 179
 t(12;21), 179
 t(9;22), 179–180
 MRD in, 190–192
 pediatric, 178
 precursor B-cell, 173–175
 precursor T-cell, 175–178
 and prognostic correlates of immunophenotypic features, 178–179
 representative cases of, 177
- Acute lymphoblastic leukemia antigen, marker controls for, 29
- Acute myelogenous leukemia (AML), 191
- Acute myeloid leukemia (AML). *See also* Leukemia
 advantages of flow cytometry in diagnosis of, 167
 antibody selection/combinations and, 169, 172–173
 assessment of MRD, 199–200
 assignment of lineage/immunophenotypic aberrancy, 193–195
 biphenotypic acute leukemia (BAL) and, 203–207
 CD45/SS and multiparameter cluster analysis, 170–171
 determination of immaturity, 192
 differential diagnostic issues
 APL vs NK/myeloid AML, 199, 201
 growth factor effect, 199
 transient myeloproliferative disorder of Down Syndrome vs AML, 199–200
 four-color antibody combinations for, 172
 gating strategies for, 168–169
 immunophenotypic/genotypic correlations
 inv(16)(p13;q22), 197–198
 t(15;17), 195–196
 t(8;21), 196–197
 therapy-related AML/11q23 abnormalities, 197
 marker controls for, 193
- Adhesion. *See* Leukocytic phagocytes
- Adult (somatic) stem cells, 321
- Adult fetal hemoglobin (HbF), monoclonal antibody production and, 296–297
- Advance Beneficiary Notice (ABN), 104
- Agammaglobulinemia, primary immunodeficiency disease and, 219–220
- Aldehyde dehydrogenase (ALDH), 335
- Allele-specific oligonucleotides (ASOs), and MRD analysis in ALL, 190–192
- Allogeneic transplantation, 322. *See also* Transplantation
 flow cytometry crossmatching and, 276–280
 and historical perspective of antibody detection, 275–276
 panel-reactive antibody (PRA) analysis
 discussion/goals, 280–281
 flow cytometric PRA (FC-PRA), 281–284
 future clinical applications, 291–292
 microparticle FC-PRA, 284–291
 single-platform ISHAGE protocol case study, 343–344
- Allowable total error (TEa), 95
- American Medical Association's Code of Medical Ethics, on payment for services, 100
- American Society for Clinical Pathology (ASCP), flow cytometry and, 11
- American Society for Histocompatibility and Immunogenetics, 280
- American Society of Clinical Oncology
 flow cytometry
 DNA content, 347
 flow cytometry and
 DNA content, 11
- Analytic measurement range (AMR)/clinical reportable range (CRR), validation protocol and, 80
- Anaplastic large cell lymphoma (ALCL). *See also* Lymphoma
 diagnosis/prognosis
 case history, 157–158
- Anchor markers, hematolymphoid neoplasia analysis and, 123–124
- Anemia
 adult fetal hemoglobin (HbF) and, 296–297
 erythropoietic activity evaluation and, 299–301
 hemolytic anemia evaluations, 301
 leukocyte glucose-6-phosphate dehydrogenase deficiency and, 255
 RBC/PMS/platelet assays and, 295
- Aneuploidy, 345–346
- Angioplasty, platelet function abnormalities and, 311
- Anthrax, multiplex bead array assays (MBAAAs) and, 111
- Antibodies. *See also* Allogeneic transplantation
 allele-specific, 290–291
 AML/ALL/MDS/MPD
 selection/combinations, 172–173
 antiplatelet, 310–311
 multiplex bead array assays (MBAAAs) and, 110
 variables to consider, 77
- Antibody panel configuration, of validation protocol, 81–82
- Antibody panel configuration validation, 81–82
- Antibody-antigen interactions
 B-cell differentiation and, 47–48
 immunologic reagents and, 7–9
 and monoclonal antibodies as reagents, 36
 T-cell differentiation and, 45–46
- Antibody-binding capacity, 25

- Antibody/reagent QC, 88
- Antigens
- abnormalities in precursor B-cell ALL, 183
 - allogeneic transplantation (single), 288–290
 - cross-lineage expression in ALL, 174–176
 - quantitative polymerase chain reaction (PCR) of, 190–192
- Antigens and biphenotypicity, 204–206
- Antihuman globulin (AHG), 275–276, 285–286
- Antinuclear antigens, multiplex bead array assays (MBAAs) and, 112
- Antiplatelet antibody, 310–311
- Apheresis, 321–322
- Aspergillus* sp., 232
- Assay optimization, 76–77
- Assays
- C3/Fc rosette, 5
 - early markers for subpopulations of T/B lymphocytes, 4–5
 - identification of viable/dead cells in, 27–28
 - initial launch preparation
 - assay modification, 82
 - initial validation to define specifications, 73
 - representative flow cytometric clinical, 16
 - surface marker
 - history/evolution, 1–2
 - problems with sheep E-rosette assays, 1–3
 - problems with slg assays, 3–4
- Ataxia telangiectasia (AT), 227
- Ataxia telangiectasia, primary immunodeficiency disease and, 232, 241–242
- Athletes, homologous transfusions of, 295
- Audits
- as component of quality assurance (QA), 73
 - QA and, 92
- Autoimmune antibodies, multiplex bead array assays (MBAAs) and, 112
- Autologous transplantation, 321–322. *See also* Transplantation
- Automation, software applications and, 66–67
- B lymphocytes. *See also* Mature B-cell malignancies
- absent/low circulating in primary immunodeficiency disease, 217, 219–220
 - early markers for subpopulations of, 4–5
 - hematopoietic cell differentiation and, 46–49
 - immunologic reagents and, 1–3
 - maturing B-cell precursor hyperplasia vs precursor B-cell acute lymphoblastic leukemia (ALL), 180–185
 - and problems with slg assays, 6–7
 - slg+ precursor B-cell ALL vs mature non-Hodgkin lymphoma
 - acute lymphoblastic leukemia (ALL), 188–189
 - in tissue sections, 6
- Babesia* infections, 301
- Bacille Calmette-Guerin, 239
- Bagwell, Bruce, 58
- Band pass optical filters, 20
- Bare Lymphocyte syndrome, 228
- Basophils, hematopoietic cell differentiation and, 40–41
- B-cell memory markers, primary immunodeficiency disease and, 229–230
- B-cell precursors
- acute lymphoblastic leukemia (ALL) and, 173–175
 - and hyperplasia vs ALL, 180–181
- BCR/ABL gene rearrangements, 179–180
- Beads, 95. *See also* Multiplex bead array systems
- Beckman-Coulter, 56–57, 66, 326–328
- Beckton-Dickinson, 56
- Becton Dickinson, 68, 264, 266, 284, 326–327
- Becton Dickinson FACSAry, 23
- Bias plot, 78–79
- Bill and Melinda Gates Foundation, 269
- Biopharmaceutical company screening, automated analysis and, 66
- Biotin-labeled RBCs, 295–296, 300
- Biphenotypic acute leukemia (BAL), 203–207
- Bleeding over of fluorescence signals, 24
- Blesing, Jack, 229
- Blood lymphocyte subset enumeration, process/assay quality control (QC) and, 88–89
- Bombay blood group, leukocyte glucose-6-phosphate dehydrogenase deficiency and, 251
- Boolean gating strategy, 325
- Breast cancer
- DNA content of solid tumors
 - standardization/new molecular technologies, 346–347
- Bronchoalveolar lavage (BAL) specimens, RBC/PMS/platelet assays and, 305–306
- BTK expression, XLA: BTK, 231
- Budgeting, and implementation of flow cytometry service, 102
- Business aspects of flow cytometry
- alternatives to implementation of service, 99–100
 - implementation of service
 - budgeting, 102
 - CPT coding/flow cytometry reimbursement, 103–104
 - ICD-9 coding/local medical review policies (LMRPS), 104–105
 - instrumentation, 100–101
 - marketing, 103
 - overhead/indirect costs, 102
 - personnel/labor/productivity, 102
 - reagents/disposals, 102
 - test pricing, 102–103
 - test volume, 100
- C3 rosette assays, T/B lymphocytes and, 5
- Calibration, 95
- CALLA. *See* Common acute lymphoblastic leukemia antigen (CALLA)
- Cancer
- and DNA content of solid tumors, 346–349
 - marker controls for malignant cells, 29
- Cancer stem cells, 321
- CAP (College of American Pathology), 74
- CAP Laboratory Accreditation Program (LAP), 92
- Capping phenomenon, T/B surface marker assay improvement and, 3–4
- Cardiopulmonary bypass, platelet function abnormalities and, 311
- Cardiovascular disease, platelet function abnormalities and, 311–312
- CBA software, 56
- CD designation nomenclature. *See* Cluster designation (CD)
- CD34 stem cell enumeration, quantitative assays and, 89–90
- CD4 T-lymphocyte testing, 267–269
- CD4+/- T-cell neoplasms, 145–146
- CDC (Centers for Disease Control and Prevention), 74
- Cell count optimization, specimen quality/quantity and, 91
- Cell cycles, DNA analysis and, 29–30
- Cell sorting, clinical flow cytometry and, 22
- CellQuest, 56
- Centers for Medicare and Medicaid Services (CMS), 103–104
- CGD (oxidative burst assay), primary immunodeficiency disease and, 237–240
- Chemotherapy
- CD34 expression as result of, 201
 - CD56 expression as result of, 201
 - and hyperplasticity due to regeneration, 180
- Children, T-lineage ALL in, 178
- Chronic granulomatous disease, 253–254
- Chronic granulomatous disease (CGD), primary immunodeficiency disease and, 232
- Chronic lymphocytic leukemia, B-cell differentiation and, 48–49
- Chronic myeloproliferative disorders (MPD). *See* Myeloproliferative disorders (MPD)
- CLIA (Clinical Laboratory Improvement Act), 74
- Clinical and Laboratory Standards Institute, 102
- Clinical Flow Cytometric Analysis of Neoplastic hematolymphoid Cells Approved Guideline*, 85
- Clinical flow cytometry. *See also* Flow cytometry
- absolute cell counts using, 28
 - cell sorting and, 22
 - cellular analysis concepts and, 16
 - clinical vs research, 21–22
 - compensation and, 24–25
 - design/operation

- electronics/computer systems, 20–21
- fluidics, 17–18
- generalities, 16–17
- optics, 18–20
- DNA analysis and, 29–30
- dual platform approach to, 28
- fluorescence/fluorochromes and, 23–24
- future and, 31–32
- gating and, 26
- image cytometry and, 22–23
- limitations of, 30–31
- quality control and, 28–29, 31
- quantitative flow cytometry and, 25
- safety considerations and, 30
- sample preparation considerations for, 26–28
- use in clinical laboratory of, 15–16
- volumetric capillary cytometry and, 23
- Clinical Laboratories Improvement Act of 1988, 30
- Clinical Laboratories Improvement Amendment (CLIA), proficiency testing (PT) and, 91
- Clinical trials, automated analysis and, 66
- Clonal LGL disorders, lymphoma analysis and, 147–148
- CLSI (Clinical Laboratory Standards Institute), 74
- Cluster designation (CD)
 - CD133 expression, 335
 - CD34+ measurement with flow cytometry
 - CD34 antigens/fluorochrome choice, 324
 - CD34+/CD3+ enumeration in allogeneic transplants, 333
 - CD45 antigens/fluorochrome choice, 325
 - commercially available assays, 327–328
 - graft assessment, 323
 - historical background, 323–324
 - immunological characterization of CD34+ stem cells, 333–334
 - isotype controls, 330
 - lysing agents, 330–331
 - quality assurance (QA) of CD34+ enumeration, 331–333
 - rare event detection, 324
 - recent developments of aldehyde dehydrogenase (ALDH), 335
 - recent developments of CD133, 335
 - single-platform CD34+ cell enumeration benefits, 329–333
 - single-platform ISHAGE protocol using TruCOUNT tubes, 328–329
 - single-platform ISHAGE protocol with viability assessment, 325–327
 - four-color combinations for AML/MDS/MPD, 172
 - hematopoietic cell differentiation
 - B cells, 46–49
 - erythrocytes, 44
 - granulocytes, 39–41
 - lymphocytes, 44–46
 - monocytes, 41–42
 - natural killer (NK) cells, 46
 - nonlymphoid, 37–38
 - platelets, 42–43
 - stem cells, 36–37
 - hematopoietic stem cell differentiation
 - CD34+ measurement
 - graft assessment, 323
 - interlaboratory standardization and, 10–12
 - mature B-cell malignancies and, 137–139
 - MDS/MPD and, 168–169
 - monoclonal surface marker assays and, 9–10
 - origin of terminology for, 9
- CMS (US Centers for Medicare and Medicaid Services), 74
- Coefficient of variation (CV), 79, 95
- Colinear, 95
- College of American Pathologists (CAP), 30, 75–76, 280, 347
- Common acute lymphoblastic leukemia antigen (CALLA), 9
 - B-cell differentiation and, 46, 49
- Common variable immune deficiency (CVID), 227
- Compensation
 - clinical flow cytometry and, 24–25
 - definition, 95
 - QC and, 86–87
- Competency assessment, QA and, 92–93
- Corrective and preventative action (CAPA), as component of quality assurance (QA), 73
- Coulter Epics, 326–327
- Counts, hematolymphoid neoplasia analysis and, 124
- Cross-lineage expression, 204–207. *See also* Acute myeloid leukemia (AML)
- Crossmatching, allogeneic transplantation and, 276–280
- Cytokine measurement, multiplex bead array assays (MBAs) and, 111
- Current Procedural Terminology (CPT) coding, 103–104
- Current Protocols in Cytometry (CPC)*, 325–326
- CVID, memory B cells in, 227, 230
- Cystic fibrosis (CFTR), multiplex bead array assays (MBAs) and, 112
- CytoConnect, 66
- Cytokines
 - and antigen changes in hematopoietic cell differentiation, 40
 - multiplex bead array assays (MBAs)
 - measurement, 111
 - reproducibility, 115
 - PBSC harvesting and, 321
- Cytologic specimens
 - DNA content of solid tumors
 - sensitivity/specificity, 348–349
- Cytometer. *See* Flow cytometer
- Cytopenias, ALL diagnosis and, 180–181
- CytoSoft software, 56
- Cytotoxicity evaluation
 - allogeneic transplantation and, 282
 - compared with MBAA, 112
- Cytotoxicity negative-adsorption positive (CYNAP), 275–276
- Dako CD34 Count Kit, 328
- DakoCytomation, 56
- Data acquisition software, 55–57
 - variables to consider, 77
- Data analysis
 - lymphoma analysis and, 131–132
 - software applications and, 57–59, 61–66
- Data Innovations Inc., 66
- Defects per million (DPMO), 93–94
- Delta-beta thalassemia, flow cytometry and, 11
- Dendritic cell generation, hematopoietic cell differentiation and, 42
- Density gradient centrifugation, hematolymphoid neoplasia analysis and, 120
- Density gradient preparation of leukocytes, 29
- Dichroic mirrors, 20
- Difference plot, 78–79
- Diffuse large mature B-cell malignancies, 140
- DiGeorge syndrome, 227
- Diphtheria, multiplex bead array assays (MBAs) and, 111
- Disposals, and implementation of flow cytometry service, 102
- DNA content
 - automated analysis and, 66
 - clinical flow cytometry and, 29–30
 - flow cytometry and, 10–11
 - fluorochromes and, 27
- DNA content of solid tumors
 - diminishing impact of flow cytometry, 345–346
 - gestational trophoblastic disease
 - new immunohistochemical stains, 349
 - obstacles in breast cancer
 - standardization/new molecular technologies, 346–347
 - obstacles in cytologic specimens
 - sensitivity/specificity, 348–349
 - obstacles in prostate cancer
 - tumor cell heterogeneity, 348
- DNA Cytometry Consensus Conference, 348
- Documentation, validation protocol and, 82
- Dual platform approach, primary immunodeficiency disease and, 217
- Dual platform approach to clinical assays, 28
- Dyes/stains. *See also* Fluorochromes
 - propidium iodide, 27
 - variables to consider, 77
- Dyserythropoiesis, adult fetal hemoglobin (HbF) and, 296–297

- Economics of health care. *See also* Business aspects of flow cytometry
and future of clinical flow cytometry, 31–32
marketing and, 103
overhead/indirect costs of implementation, 102
personnel/labor/productivity and, 102
test pricing, 102–103
- Electronic gating. *See* Gating
- Electronics/computer systems, of flow cytometer, 20–21
- ELISAs, multiplex bead array assays (MBAAAs) and, 108, 111–114
- Embryonic stem cells, graft assessment using flow cytometry, 321
- Enzyme histochemistry, T_H lymphocytes and, 5
- Eosinophils, hematopoietic cell differentiation and, 40–41
- Epstein-Barr virus, multiplex bead array assays (MBAAAs) and, 111
- Erythrocytes
hematopoietic cell differentiation and, 44
monoclonal surface marker assays and, 4
- Erythropoietic activity evaluation, RBC/PMS/platelet assays and, 299–301
- Escheria coli*, 255
- Ethylenediaminetetraacetic acid (EDTA), hematolymphoid neoplasia analysis and, 119–120
- European Working Group on Clinical Cell Analysis (EWGCCA), 326, 329
- Excisional biopsy for liquid sample, hematolymphoid neoplasia analysis and, 120–121
- Expo32 CXP/RXP software, 56
- Extensible Markup Language (XML), 57
- External proficiency testing (PT) programs, 91
- Extrinsic properties of cytometer light scatter, 19, 31
- Facilities, and implementation of flow cytometry service, 101
- FACSCount, 264–266
- FACSDiva software, 56
- Fc rosette assays, T/B lymphocytes and, 5
- F-cell detection/fetomaternal hemorrhage (FMH), RBC/PMS/platelet assays and, 296–298
- FCS standard file reading, 56, 58
- FCSEXPRESS, 58, 65, 68
- Fetomaternal hemorrhage (FMH)/F-cell detection, RBC/PMS/platelet assays and, 296–298
- Fetomaternal hemorrhage, flow cytometry and, 11
- Ficol preparation, hematolymphoid neoplasia analysis and, 120
- Final Rule and Laboratory Accreditation Program, 75–76
- Fine-needle aspiration (FNA) for liquid sample
hematolymphoid neoplasia analysis and, 120–121
- Flow cytometer
design/operation
electronics/computer systems, 20–21
fluidics, 17–18
generalities, 16–17
optics, 18–20
quality control and, 28
- Flow cytometric crossmatch (FCXM), 276–280
- Flow cytometric PRA (FC-PRA), 281–284
- Flow cytometric PRA (FC-PRA) (microparticle), 284–291
- Flow cytometry
absolute cell counts using, 28
anaplastic large cell lymphoma (ALCL)
case history, 158
cell sorting and, 22
cellular analysis concepts and, 16
clinical vs research, 21–22
compensation and, 24–25
design/operation
electronics/computer systems, 20–21
fluidics, 17–18
generalities, 16–17
optics, 18–20
diagnostic laboratory applications for, 10–12
DNA analysis and, 29–30
fluorescence/fluorochromes and, 23–24
future of, 31–32
gating and, 26
hairy cell leukemia variant
case history, 165
hepatosplenic $\gamma\delta$ T-cell lymphoma
case history, 162
image cytometry and, 22–23
limitations of, 30–31
mature T-cell malignancies
case history, 160
quality control and, 28–29, 31
quantitative flow cytometry and, 25–26
safety considerations and, 30
sample preparation considerations for, 26–28
use in clinical laboratory of, 15–16
volumetric capillary cytometry and, 23
- Flow cytometry reimbursement, 103–104
- FlowJo, 58, 64–65
- FlowMax software, 56
- Flow-PRA, for detection of anti-HLA antibodies, 110, 114
- Fluidics of flow cytometer, 17–18
- Fluorescein isothiocyanate (FITC), 24, 323
- Fluorescein-conjugated antibodies, dead T/B lymphocytes and, 3–4
- Fluorescence
acute myeloid leukemia (AML) and, 171
clinical flow cytometry and, 23–24
FCXM and, 279–280
gating and, 26
multiplex bead array assays (MBAAAs) and, 107–108
- Fluorescent in situ hybridization (FISH), 347
- Fluorochromes
CD34+ measurement with flow cytometry, 324–325
clinical flow cytometry and, 23–24
primary immunodeficiency disease and, 216
- Food and Drug Administration (FDA)
FDA-approved (IVD) assay, 75
and in-vitro diagnostics use of new assays, 75
- Frequency distribution histograms, 59–61, 63
- Gated vs whole specimen multicolor, hematolymphoid neoplasia analysis and, 124–126
- Gating
for AML/ALL/MDS/MPD, 168–169
CD34+ measurement by multiparameter Boolean, 325
of CD45 in hematopoietic cell differentiation, 38
clinical flow cytometry and, 26
data analysis and, 61–63
for FCXM, 278
HIV/AIDS and, 261–266
Gene rearrangements and ALL, 179–180
- Genetic testing. *See also* Primary immunodeficiency disease
multiplex bead array assays (MBAAAs) and, 112
- German Reference Protocol, 326–327
- Gestational trophoblastic disease
DNA content of solid tumors
new immunohistochemical stains, 349
- Giardia lamblia*, 219
- Glycosyl phosphatidylinositol (GPI), 298
- Good manufacturing practices (GMP), 95
- Good, Robert, 321
- GPIIb/IIIa site marker of platelets, 311
- Graft adequacy/quality, 322–323, 335
- Granulocyte colony-stimulating factor (G-CSF), 341
- Granulocytes
hematopoietic cell differentiation and, 36, 39–41
monoclonal surface marker assays and, 4
- Growth of cells, DNA analysis and, 29–30
- Guava EasyCyte system, 56
flow cytometers of, 18
- Guava Technologies EZCD4 (CD4 T-lymphocyte testing), 267
- Guidelines. *See* Regulations/guidelines/references
- Haemophilus influenzae*, 219
- Haplo-identical transplant, 322
- Health Information Portability and Accountability Act (HIPAA), 59
- Hematogones. *See also* Maturing B-cell precursor hyperplasia
vs precursor B-cell
immunophenotypic features, 184
maturation spectrum of, 181–182
quantitative maturation analysis/stages of, 183
- Hematology analyzers, 23

- Hematolymphoid neoplasia analysis
analytic concepts
anchor markers, 123–124
counts, 124
gated vs whole specimen multicolor, 124–126
multicolor analysis, 123
single gate vs multiple gates, 124
postanalytic concepts
interpretation, 124
reporting content, 125, 127
reporting turnaround time, 127
preanalytic concepts
clinical/morphologic triage, 121–122
liquid sample collection/transportation, 119–120
panel selection considerations, 123
sample type, 122–123
solid tissue sample collection/transportation, 120–121
- Hematopoietic cell differentiation. *See also* Paroxysmal nocturnal hemoglobinuria (PNH)
CD designation nomenclature
B cells, 46–49
erythrocytes, 44
granulocytes, 39–41
lymphocytes, 44–46
monocytes, 41–42
natural killer (NK) cells, 46
nonlymphoid, 37–38
platelets, 42–43
stem cells, 36–37
monoclonal antibodies and, 35
- Hematopoietic stem cell (HSPCs) identification
assessment of graft adequacy, 322–323
bone marrow types/PBSC transplantation
allogeneic transplant, 322
autologous transplant, 321–322
- CD34+ measurement with flow cytometry
CD34 antigens/fluorochrome choice, 324
CD34+/CD3+ enumeration in allogeneic transplants, 333
CD45antigens/fluorochrome choice, 325
commercially available assays, 327–328
historical background, 323–324
immunological characterization of CD34+ stem cells, 333–334
isotype controls, 330
lysing agents, 330–331
quality assurance (QA) of CD34+ enumeration, 331–333
rare event detection, 324
recent developments of aldehyde dehydrogenase (ALDH), 335
recent developments of CD133, 335
single-platform CD34+ cell enumeration benefits, 329–333
single-platform ISHAGE protocol using TruCOUNT tubes, 328–329
single-platform ISHAGE protocol with viability assessment, 325–327
- definitions, 321
graft assessment using flow cytometry, 323
historical background, 321
stem cell collection and bone marrow harvesting, 322
- Hemoglobinopathies
adult fetal hemoglobin (HbF) and, 296–297
multiplex bead array assays (MBAAAs) and, 112
paroxysmal nocturnal hemoglobinuria (PNH) and, 298
- Hemolytic anemia
leukocyte glucose-6-phosphate dehydrogenase deficiency and, 255
RBC/PMS/platelet assays and, 301
- Hemophilus influenzae type B, multiplex bead array assays (MBAAAs) and, 111–112
- HER2-associated growth promotion, 347
- Historical databases, quality control and, 28
- HLA typing. *See also* Allogeneic transplantation
multiplex bead array assays (MBAAAs) and, 109–111
- HLA-DR expression, primary immunodeficiency disease and, 225–228
- Hodgkin lymphoma, autologous transplantation and, 321
- Human immunodeficiency virus (HIV). *See also* Acquired immunodeficiency syndrome (AIDS)
Bill and Melinda Gates Foundation and, 269
and immunophenotyping for CD4 lymphocytes, 11
lymphocyte immunophenotyping
flow cytometry, 261–267
future of CD4 T-lymphocyte testing, 267–269
history, 259–261
- Human leukocyte antigen (HLA), 321
- Hydrogen bonds of antibody-antigen interactions, 6
- Hyper IgE syndrome (HIGM) syndromes
function-based procedures
X-linked HIGM syndrome (CD40 ligand measurement), 232, 235–238
specialized monoclonal antibody panels
memory B cells in CVID/HIGM syndromes, 230
primary immunodeficiency disease, 231
- HyperLog, 58
- Hypoxanthine/guanine phosphoribosyl transfers (HGPRT), monoclonal antibody production and, 8
- ICD-9 coding/local medical review policies (LMRPS), 104–105
- i-Cyt Visionary Biosciences, 66
- Identical twin transplants, 322
- Image cytometry, 22–23
clinical flow cytometry and, 22–23
- Immature reticulocyte fraction (IRF), erythropoietic activity evaluation and, 299–301
- Immunodeficiency disease. *See* Primary immunodeficiency disease
- Immunohistochemical stains, 349
- Immunological characterization of CD34+ stem cells, 333–334
- Immunophenotyping (routine)
abnormal HLA-DR expression, 225–228
absent/low circulating B lymphocytes, 217, 219–220
CVID/AT/DiGeorge syndrome, 227
decreased CD4+ T cells, 227
decreased CD8+ T cells, 227
definition, 95
leukemia and, 30
SCID syndrome (Omenn syndrome), 224–225
SCID syndrome (overview of findings), 225
SCID syndrome (Th–, Tc–, B–, NK–), 224
SCID syndrome (Th–, Tc–, B–, NK+), 221, 223
SCID syndrome (Th–, Tc–, B+, NK–), 221
SCID syndrome (Th–, Tc–, B+, NK+), 221
SCID syndrome (Th–, Tc–, NK–, B+), 221–222
SCID syndrome (Th+, Tc+, B+, NK–), 224
SCID syndrome generalities, 219, 221
- Immunoplatelet count. *See* Platelets
- Independently validated assays (ASR), 75–76
- Instrument correlation, QC and, 87–88
- Instrumentation, and implementation of flow cytometry service, 100–101
- Integrated Cytometry System, 66
- Integrated signal processing, 20–21
- Integrins, leukocytic phagocytes and, 248–249
- Interassay precision, 79–80
- Intercellular adhesion molecules (ICAMs), leukocytic phagocytes and, 248
- Interferon α
and antigen changes in hematopoietic cell differentiation, 40
primary immunodeficiency disease and, 239–242
- Internal proficiency testing (PT) programs, 91–92
- International Bone Marrow Transplant Registry (IMBTR), 321
- International Classification of Diseases, 9th Revision (ICD-9)*¹³
codes, 104
- International Society for Laboratory Hematology (ISLH), 308–309
- International Society of Hematotherapy and Graft Engineering (ISHAGE), 325–328, 331–333, 343–344
- International Standards Organization (ISO), 94
- International Workshops on Human Leukocyte Differentiation Antigens, 35–36
- Interstitial lung disease, bronchoalveolar lavage (BAL) specimens and, 305–306

- Intra-assay precision, 79
 Intrinsic properties of cytometer light scatter, 19, 30–31
 Investigational use only (IUO) assay, 75
 In-vitro diagnostics use of new assays, 75
 Ionic bonds of antibody-antigen interactions, 6
 ISHAGE (International Society of Hemotherapy and Graft Engineering), 74
 Isotype controls and CD34+ enumeration, 330
 IVD assay, 75
- JCAHO (Joint Commission on Accreditation of Healthcare Organizations), 74
 Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 92
- Kaposi syndrome, 259
 Kleihauer-Betke (KB), 279
 Kleihauer-Betke acid elution test, fetal hemoglobin and, 11
- LabNow Microchip technologies (CD4 T-lymphocyte testing), 268–269
 Labor, and implementation of flow cytometry service, 102
 Laboratory information system (LIS), 66
 LANs and offline analysis, 57
 Laser light of flow cytometers. *See* Optics
 Lentiviruses, 260
 Leucine-rich repeat-containing 8 gene (LRRC8), 219
 Leukemia. *See also* Hematolymphoid neoplasia analysis
 acute lymphoblastic leukemia
 marker controls for, 29
 acute myelogenous leukemia (AML), 203–207
 automated analysis and, 66
 and CD34 as hematopoietic stem cell marker, 36
 chronic lymphocytic leukemia
 B-cell differentiation, 48–49
 immunophenotyping and, 30
 Leukemia diagnosis/prognosis
 CD4- T-cell neoplasms, 146
 CD4+ T-cell neoplasms, 145–146
 data analysis and, 131–132
 detection of mature NK-cell malignancies, 146–147
 diagnosis of clonal LGL disorders, 147–148
 hairy cell leukemia variant
 case history, 164–165
 hepatosplenic $\gamma\delta$ T-cell lymphoma
 case history, 161–163
 indicators in lymphoproliferative disorders, 148–150
 mature B-cell malignancies
 CD10+, 138
 CD11c/cytoplasmic projections, 138–139
 CD5+, 137–138
 detection, 132–136
 diffuse large, 140
 immunophenotypic data, 136
 MALT/primary effusion lymphomas, 141
 plasma cell disorders, 139–140
 mature T-cell malignancies
 case history, 159–160
 diagnosis, 141–144
 subclassifications, 144–145
 panel design for, 130
 small specimens and, 130–131
 specimen preparation for, 129–130
 Leuko64, 303–304
 Leukocyte adhesion deficiency (LAD) disorders
 biology of leukocyte adhesion, 247–249
 LAD I, 235–237, 249–250
 LAD II (Rambon-Hasharon syndrome), 251
 neonatal leukocyte adhesion abnormalities, 251–252
 specific granule deficiency, 251
 Leukocyte glucose-6-phosphate dehydrogenase deficiency, 255
 Leukocytes. *See also* Hematolymphoid neoplasia analysis
 density preparation of, 29
 erythrocyte removal in analysis of, 27–28
 human leukocyte antigen (HLA), 321
 Leuko64 and, 303–304
 whole blood lysis preparation of, 29
 Leukocytic phagocytes
 chronic granulomatous disease, 253–254
 killing disorders
 oxygen-dependent mechanisms, 252–253
 oxygen-independent mechanisms, 252
 leukocyte adhesion deficiency (LAD) disorders
 biology of leukocyte adhesion, 247–249
 LAD I, 249–250
 LAD II (Rambon-Hasharon syndrome), 251
 neonatal leukocyte adhesion abnormalities, 251–252
 specific granule deficiency, 251
 leukocyte glucose-6-phosphate dehydrogenase deficiency, 255
 myeloperoxidase deficiency (MPO), 254–255
 Levy-Jennings control chart/plots
 definition, 95
 QC and, 89
 Ligand induced binding site marker of platelets, 311
 Linearity, 87, 95
 LISPort, 68
Listeria sp., 241
 Local medical Review Policies (LMRPS), 104
 Logicle, 58
 Long pass optical filters, 20
 Luminex 100 bead array system, 23
 Luminex technology, microparticle FC-PRA and, 284, 286
 Luminex xMAP, 56
 Lymphocytes
 absent/low circulating B lymphocytes, 217, 219–220
 automated analysis and, 66
 B
 early markers for subpopulations, 4–5
 immunologic reagents, 1–3
 in tissue sections, 6
 BAL activation markers for, 306
 enzyme histochemistry and, 5
 flow cytometry and function of, 10
 hematopoietic cell differentiation and, 44–46
 immunophenotyping
 flow cytometry for HIV, 261–267
 future of CD4 T-lymphocyte testing, 267–269
 HIV history, 259–261
 integrins and, 248–249
 intrinsic properties of, 19–20
 primary immunodeficiency diseases and, 215
 T
 early markers for subpopulations, 4–5
 immunologic reagents, 1–3
 in tissue sections, 6
 and validation parameters of accuracy, 78
 Lymphoma, autologous transplantation and, 321
 Lymphoma diagnosis/prognosis. *See also* Hematolymphoid neoplasia analysis
 automated analysis and, 66
 CD4- T-cell neoplasms, 146
 CD4+ T-cell neoplasms, 145–146
 data analysis and, 131–132
 detection of mature NK-cell malignancies, 146–147
 diagnosis of clonal LGL disorders, 147–148
 hairy cell leukemia variant
 case history, 164–165
 hepatosplenic $\gamma\delta$ T-cell lymphoma
 case history, 161–163
 indicators in lymphoproliferative disorders, 148–150
 mature B-cell malignancies
 CD10+, 138
 CD11c/cytoplasmic projections, 138–139
 CD5+, 137–138
 detection, 132–136
 diffuse large, 140
 immunophenotypic data, 136
 MALT/primary effusion lymphomas, 141
 plasma cell disorders, 139–140
 mature T-cell malignancies
 case history, 159–160
 diagnosis, 141–144
 subclassifications, 144–145
 panel design for, 130
 small specimens and, 130–131
 specimen preparation for, 129–130
 Lymphopenia
 primary immunodeficiency diseases and, 216
 SCID syndrome (Th-, Tc-, B-, NK-) and, 224

- Lymphoproliferative disorders, lymphoma analysis and, 148–150
- Lysing agents and CD34+ enumeration, 330
- Lysosomal marker of platelets, 311
- Macrophages, BAL activation markers for, 306
- Major histocompatibility complex (MHC), 322
- Malignant cells, marker controls for, 29
- MALT/primary effusion lymphomas, mature B-cell malignancies and, 141
- Management Sciences Associates, 66, 68
- Maternal antibodies. *See* Adult fetal hemoglobin (HbF)
- Mature B-cell malignancies
- CD10+, 138
 - CD11c/cytoplasmic projections, 138–139
 - CD5+, 137–138
 - detection, 132–136
 - diffuse large, 140
 - immunophenotypic data, 136
 - MALT/primary effusion lymphomas, 141
 - plasma cell disorders, 139–140
- Mature NK-cell malignancies, 146–147
- Mature non-Hodgkin lymphoma, vs slg+ precursor B-cell ALL, 188–189
- Mature T-cell malignancies
- diagnosis. *See also* Mature T-cell malignancies subclassifications, 144–145
- Maturing B-cell precursor hyperplasia vs precursor B-cell, acute lymphoblastic leukemia (ALL) and, 180–185
- Mean equivalent of soluble fluorescein (MESF), 303
- quantitative flow cytometry and, 25
- Medicare/Medicaid
- Centers for Medicare and Medicaid Services (CMS), 103–104
 - ICD-9 codes and, 104
 - Local Medical Review Policies (LMRPS) and, 104
 - on mark-up of charges, 99–100
- Megakaryocytes, hematopoietic cell differentiation and, 43
- memory B cells in CVID/HIGM syndromes, primary immunodeficiency disease and, 230
- Method validation (MV), 95
- Microparticle FC-PRA, 284–291
- Microsoft, 67–68
- Microsoft Windows, 55
- Minimal residual disease (MRD)
- in ALL
 - analysis, 190–192
 - hematolymphoid neoplasia analysis and, 121
- Molecules of equivalent soluble fluorochrome (MESF), 279–280
- Monoclonal antibodies, hematopoietic cell differentiation and, 35–36
- Monoclonal antibody panels
- ataxia telangiectasia, 232
 - B-cell memory markers, 229–230
 - chronic granulomatous disease (CGD), 232
 - HIGM syndromes, 231
 - memory B cells in CVID/HIGM syndromes, 230
 - T-cell receptor V β repertoire analysis in CD4/CD8 T-cell subsets, 229
 - Wiscott-Aldrich syndrome (WAS), 232–234
 - XLA: BTK, 231
 - X-linked SCID: γ c/CD132, 231
- Monoclonal antibody production, 225–228
- adult fetal hemoglobin (HbF) and, 296–297
 - graft adequacy assessment and, 322–323
 - immunologic reagents and, 7–9
 - paroxysmal nocturnal hemoglobinuria (PNH) and, 298–299
 - platelet activation markers of, 311
 - primary immunodeficiency diseases and, 215–216
 - RBC/PMS/platelet assays and, 295
 - trastuzumab and, 347
- Monocyte activation changes, RBC/PMS/platelet assays and, 305
- Monocytes
- BAL activation markers for, 306
 - hematopoietic cell differentiation and, 41–42
- Mononuclear cell count (MNC), as predictor of graft adequacy, 322
- Multicolor analysis, hematolymphoid neoplasia analysis and, 123
- Multicolor approach to flow cytometry, 31
- Multicycle, 58
- Multidrug resistance (MDR), hematopoietic cell differentiation and, 37
- Multiple myeloma
- autologous transplantation and, 321
 - B-cell differentiation and, 49
- Multiple myeloma, case study, 341–342
- Multiplex bead array assays (MBAAs)
- basic principles/theory, 23, 107–110
 - clinical applications
 - autoimmune antibodies, 112
 - cytokine measurement, 111
 - genetic testing, 112
 - HLA typing, 109–111
 - panel-reactive antibodies, 110
 - pathogen detection, 111–112 - comparison with other techniques, 112–114
 - sensitivities/reproducibility/stability of, 114–115
- Mycobacteria* sp., 239, 241
- Myeloblasts, hematopoietic cell differentiation and, 39–40
- Myelodysplasia, hematolymphoid neoplasia analysis and, 120
- Myelodysplastic syndromes (MDS)
- abnormalities of maturation spectrum and, 203
 - adult fetal hemoglobin (HbF) and, 296–297
 - advantages of flow cytometry in diagnosis of, 167
 - antibody selection/combinations and, 169, 172–173
 - CD34+ diagnosis of, 200–201
 - four-color antibody combinations for, 172
 - gating strategies for, 168–169
- Myeloperoxidase deficiency (MPO), 254–255
- Myeloproliferative disorders (MPD)
- abnormalities of maturation spectrum and, 203
 - advantages of flow cytometry in diagnosis of, 167
 - antibody selection/combinations and, 169, 172–173
 - CD34+ diagnosis of, 200–201
 - four-color antibody combinations for, 172
 - gating strategies for, 168–169
- National Committee for Clinical Laboratory Standards (NCCLS), 102
- National Institute of Standards and Technology (NIST), 303
- Natural killer (NK) cells
- hematopoietic cell differentiation and, 46
 - SCID syndromes and, 221–226
- NCCLS. *See* CLSI (Clinical Laboratory Standards Institute)
- Neisseria meningitidis*, multiplex bead array assays (MBAAs) and, 111
- Neonatal transfusion therapy
- RBC assays and, 296
- Neoplasms
- flow cytometry
 - DNA content, 10–11
- Neutrophil CD64 quantitation, RBC/PMS/platelet assays and, 301–305
- Neutrophil transdifferentiation, hematopoietic cell differentiation and, 40–41
- NK-cell malignancies, lymphoma analysis and, 146–147
- Nocardia* sp., 232
- Non-Hodgkin lymphoma
- autologous transplantation and, 321
 - HIV and, 259
 - vs slg+ precursor B-cell ALL, 188–189
- Nonlymphoid cells, hematopoietic cell differentiation and, 37–38
- Obstructive sleep apnea syndrome, platelet function abnormalities and, 311
- Occupational Safety and Health Administration (OSHA), 30
- Off-label assays, 75
- Offline analysis software, 57–59
- Omenn syndrome, 224–226
- Optics, of flow cytometer, 18–20
- Optimization of cell counts, specimen quality/quantity and, 91
- Ortho Cytoron Absolute, 264
- Overton subtraction method, 63
- Oxidative burst assay (CGD), 237–240

- Panel selection/design
 hematolymphoid neoplasia analysis and, 123
 lymphoma analysis and, 130
- Panel-reactive antibodies
 multiplex bead array assays (MBAAs) and, 110
- Panel-reactive antibody (PRA) analysis
 allogeneic transplantation
 discussion/goals, 280–281
 flow cytometric PRA (FC-PRA), 281–284
 future clinical applications, 291–292
 microparticle FC-PRA, 284–291
- PanLeucoGating method, 266–267
- Parasite infections, RBC/PMS/platelet assays and, 301
- Paroxysmal nocturnal hemoglobinuria (PNH),
 RBC/PMS/platelet assays and, 298–299
- Partec, 56
- Partec CyFlow Counter (CD4 T-lymphocyte testing),
 267–268
- Pathogen detection, multiplex bead array assays (MBAAs)
 and, 111–112
- Peak-sense-and-hold signal processing, 20–21
- Peridinin chlorophyll protein (PerCP), 24
- Peripheral blood stem cells (PBSCs), 321
- Peripheral T-cell lymphoma, vs precursor T-lymphoblastic
 lymphoma/leukemia, 190
- Phagocytes. *See* Leukocytic phagocytes
- Photomultiplier tubes (PMTs), 20
- Phycocerythrin (PE), 24, 323
- Plasma cell disorders, mature B-cell malignancies and,
 139–140
- Plasmodium infections, 301
- Platelet associated immunoglobulin, 310–311
- Platelets
 antiplatelet antibodies and, 310–311
 count of, 307–309
 function/kinetics of, 306–307
 hematopoietic cell differentiation and, 42–43
 methods/clinical applications of flow cytometry, 306
 platelet function abnormalities, 311–312
 reticulated, 309–310
- Ploidy determination, DNA analysis and, 29
- PMN CD64 assay rationale, 302–303
- Pneumocystis carinii*, 259
- PointCare Technologies AuRICA (CD4 T-lymphocyte
 testing), 268
- Polyclonal antibody production, immunologic reagents and,
 7–8
- Polymorphonuclear neutrophils (PMNs)
- Population analysis vs single-cell analysis, 16
- Portable document format (PDF) files, 69
- Positive/negative controls, quality control and, 28–29
- Postanalytical process, 95
- Preanalytical process, 95
- Precision
 definition, 95
 quality control (QC) and, 73
 validation protocol and, 79–80
- Precursor B-cell, acute lymphoblastic leukemia (ALL) and,
 173–175, 183
- Precursor B-cell ALL, MRD analysis in, 191
- Precursor T-cell, acute lymphoblastic leukemia (ALL) and,
 175–178
- Precursor T-lymphoblastic lymphoma/leukemia
 vs peripheral T-cell lymphoma, 190
 vs peripheral T-cell lymphoma, 194
 vs thymoma, 185–188
- Primary immunodeficiency disease
 function-based procedures
 ataxia telangiectasia, 241–242
 CGD (oxidative burst assay), 237–240
 interferon α pathway defects (mycobacterial
 infections), 239–242
 leukocyte adhesion deficiency (LAD) type-1,
 235–237
 X-linked HIGM syndrome (CD40 ligand
 measurement), 232, 235–238
 routine immunophenotyping, 216–218
 abnormal HLA-DR expression, 225–228
 absent/low circulating B lymphocytes, 217, 219–220
 CVID/AT/DiGeorge syndrome, 227
 decreased CD4+ T cells, 227
 decreased CD8+ T cells, 227
 SCID syndrome (Omenn syndrome), 224–226
 SCID syndrome (overview of findings), 225
 SCID syndrome (Th–, Tc–, B–, NK–), 224
 SCID syndrome (Th–, Tc–, B–, NK+), 221, 223
 SCID syndrome (Th–, Tc–, B+, NK–), 221
 SCID syndrome (Th–, Tc–, B+, NK+), 221
 SCID syndrome (Th–, Tc–, NK–, B+), 221–222
 SCID syndrome (Th+, Tc+, B+, NK–), 224
 SCID syndrome generalities, 219, 221
- specialized monoclonal antibody panels
 ataxia telangiectasia, 232
 B-cell memory markers, 229–230
 chronic granulomatous disease (CGD), 232
 HIGM syndromes, 231
 memory B cells in CVID/HIGM syndromes, 230
 T-cell receptor $V\beta$ repertoire analysis in CD4/CD8 T-
 cell subsets, 225–227, 229
 Wiscott-Aldrich syndrome (WAS), 232–234
 XLA: BTK, 231
 X-linked SCID: γ /CD132, 231
- ProCOUNT assay, 327
- Productivity, and implementation of flow cytometry service,
 102
- Proficiency testing (PT)
 as component of quality assurance (QA), 73
 definition, 95
- Progenitor cell identification
 CD34+ measurement with flow cytometry
 CD34 antigens/fluorochrome choice, 324
 CD34+/CD3+ enumeration in allogeneic transplants,
 333
 CD45 antigens/fluorochrome choice, 325
 commercially available assays, 327–328
 historical background, 323–324
 immunological characterization of CD34+ stem cells,
 333–334
 isotype controls, 330
 lysing agents, 330–331
 quality assurance (QA) of CD34+ enumeration,
 331–333
 rare event detection, 324
 recent developments of aldehyde dehydrogenase
 (ALDH), 335
 recent developments of CD133, 335
 single-platform CD34+ cell enumeration benefits,
 329–333
 single-platform ISHAGE protocol using TruCOUNT
 tubes, 328–329
 single-platform ISHAGE protocol with viability
 assessment, 325–327
- Propidium iodide
 as stain, 27
- Prostate cancer
 DNA content of solid tumors
 tumor cell heterogeneity, 348
- P-Selectin marker of platelets, 311–312
- Pseudomonas aeruginosa*, 251
- Qualitative assays
 definition, 95
 QA and, 90
- Quality assurance (QA). *See also* Hematolymphoid neoplasia
 analysis
 assay optimization and, 76–77
 CD34+ measurement and, 331–333
 competency assessment and, 92–93
 components of, 73
 definition, 95
 initial assay launch preparation, 82
 and new assay validation, 74–76
 proficiency testing and, 91–92
 qualitative assays, 90
 quality audits and, 92
 quality control (QC) and
 antibody/reagent QC, 88
 compensation, 86–87
 instrument correlation, 87–88
 instrument QC, 83–86
 linearity, 87
 quality improvement and, 93

- quality programs and, 93–94
 quantitative assays
 blood lymphocyte subset enumeration, 88–89
 CD34 stem cell enumeration, 89–90
 quantitative assays and, 90
 specimen quality/quantity
 optimization of cell counts, 91
 viability assessment, 90–91
 training programs and, 92
 validation protocol
 accuracy, 77–79
 analytic measurement range (AMR)/clinical reportable range (CRR), 80
 analytic sensitivity, 80
 analytic specificity, 80
 documentation, 82
 precision, 79–80
 reference interval, 81
 sample handling, 81
 stability, 80–81
 validation of antibody panel configuration, 81–82
 web sites for, 95
 Quality audits. *See* Audits
 Quality control (QC)
 antibody/reagent QC and, 88
 compensation and, 86–87
 as component of quality assurance (QA), 73
 definition, 96
 instrument correlation and, 87–88
 instrument QC, 83–86
 linearity and, 87
 Quality control, clinical flow cytometry and, 28–29
 Quality improvement (QI), as component of quality assurance (QA), 73
 Quantitative assays
 blood lymphocyte subset enumeration, 88–89
 CD34 stem cell enumeration and, 89–90
 definition, 95
 Quantitative flow cytometry, clinical flow cytometry and, 25
 Quantitative polymerase chain reaction (PCR), and MRD analysis in ALL, 190–192
 Rambon-Hasharon syndrome, as LAD, 251
 Reagents/disposals, and implementation of flow cytometry service, 102
 Red blood cells (RBCs)
 bronchoalveolar lavage (BAL) specimens and, 305–306
 erythropoietic activity evaluation, 299–301
 fetomaternal hemorrhage/F-cell detection in, 296–298
 hemolytic anemia evaluations, 301
 immunohematology and, 295–296
 monocyte activation changes
 sepsis, 305
 neutrophil CD64 quantitation
 infection/sepsis, 301–305
 parasite infections and, 301
 paroxysmal nocturnal hemoglobinuria and, 298–299
 Reference interval, validation protocol and, 81
 Reference laboratories, as alternative services, 99–100
 Regulations/guidelines/references
 agencies/publications for, 74
 quality assurance (QA) and, 73–74
 Reliability, quality control (QC) and, 73
 Renal dialysis, platelet function abnormalities and, 311
 Reporting content/turnaround time, hematolymphoid neoplasia analysis and, 125, 127
 Reproducibility of results, quality control (QC) and, 73
 Research flow cytometers, vs clinical, 21–22
 Research use only (RUO) assay, 75
 Respiratory viruses, multiplex bead array assays (MBAAs) and, 111
 Reticulated platelets, 309–310
 Reticulocyte assays, flow cytometry and, 10
 Retrovirus. *See* Human immunodeficiency virus (HIV)
 Rh immune globulin therapy, RBC assays and, 297
 Robinson-Patman Act, 103
 Roederer, Mario, 64–65
 rosebud, 383
 RUO/IUO assay, 75
 RVUs. *See* Current Procedural Terminology (CPT) coding
 Safety considerations, clinical flow cytometry and, 30
Salmonella sp., 239, 241
 Sample handling/preparation
 hematolymphoid neoplasia analysis and, 119–121
 lymphoma analysis and, 130–131
 quality control and, 28–29
 validation protocol and, 81
 variables to consider, 77
 Sample Prep Assisant, 66
 Sample preparation considerations, for clinical flow cytometry, 26–28
 Sample preparation, quality control and, 31
 Sample type, hematolymphoid neoplasia analysis and, 122–123
 Sarcoid disease, bronchoalveolar lavage (BAL) specimens and, 305–306
 Scatter, and gating strategy of Milan-type protocols, 323
 SCID syndrome
 generalities, 219, 221
 Omenn syndrome, 224–226
 overview of findings, 225
 Th-, Tc-, B-, NK-, 224
 Th-, Tc-, B-, NK+, 221, 223
 Th-, Tc-, B+, NK-, 221
 Th-, Tc-, B+, NK+, 221
 Th-, Tc-, NK-, B+, 221–222
 Th+, Tc+, B+, NK-, 224
 Semibio CD4 Count Chip Kit, 269
 Sensitivity
 definition, 96
 DNA content and, 348
 validation protocol and, 80
 Sepsis
 monocyte activation changes and, 305
 neutrophil CD64 quantitation for, 301–305
Serratia marcescens, 232
 Severe combined immunodeficiency (SCID), 321
 Sheep E-rosette assays, T/B lymphocytes and, 1–3
 Sherman Act, 103
 Short pass optical filters, 20
 Sick cell disease
 adult fetal hemoglobin (HbF) and, 296–298
 flow cytometry and, 11
 sIg+ precursor B-cell ALL vs mature non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and, 188–189
 slgs
 T_H lymphocytes and, 5
 T/B lymphocytes and, 3–4
 Simian immunodeficiency virus (SIV), 260
 Single gate vs multiple gates, hematolymphoid neoplasia analysis and, 124
 Single platform approach, primary immunodeficiency disease and, 217
 Six Sigma, 93, 96
 Sodium heparin, hematolymphoid neoplasia analysis and, 119–120
 Software applications
 automation and, 66–67
 data analysis and, 61–66
 data display and, 59–61
 data-acquisition software, 55–57
 exporting results, 67–69
 offline analysis, 57–59
 variables to consider, 77
 Somatic stem cells, 321
 Southeastern Organ Procurement Foundation, 280
 Specimen handling, quality control and, 28–29
 Specimen quality/quantity, and optimization of cell counts, 91
 Stability, validation protocol and, 80–81
 Stains. *See* Dyes/stains
 Standard deviation (SD), 79, 96
 Standardization of techniques
 importance of, 31
 variables of, 77
Staphylococcus aureus, 219

- StarStation software, 56
 Statistical tools, 78–79
 Stem cells. *See also* Hematopoietic stem cell (HPSCs)
 identification
 collection of, 322
 hematopoietic cell differentiation and, 36–37
 Stem-Kit, 327–328
 Stokes' shift, 23–24
Streptococcus aureus, 219, 232, 250–251, 255
Streptococcus marcescens, 255
Streptococcus pneumoniae, 219
 multiplex bead array assays (MBAAs) and, 111
 Stroke, platelet function abnormalities and, 311
 Summit software, 56
 Super enhanced Dmax subtraction (SED), 63
 Surface marker assays
 activated T-cell rosette assay and, 5
 assay problems, 3–4
 C3/Fc rosette assays and, 5
 early markers for subpopulations of T/B lymphocytes,
 4–5
 enzyme histochemistry
 T_H lymphocytes and, 5
 history/evolution of, 1–2
 immunologic reagents
 antibody-antigen interactions, 6–7
 polyclonal/monoclonal antibody production, 7–9
 interlaboratory standardization of CD monoclonal
 antibodies and, 10–12
 pre-flow cell surface assay correlation with monoclonal
 markers, 9–10
 Suspensions, importance of monodispersed, 17–18
 Syngeneic transplants, 322
- T lymphocytes
 as differ from NK cells, 46
 early markers for subpopulations of, 4–5
 hematopoietic cell differentiation and, 44–46
 immunologic reagents and, 1–3
 mature T-cell malignancies, 144–146
 and precursor T-lymphoblastic lymphoma/leukemia vs
 thymoma, 185–188
 precursor T-lymphoblastic lymphoma/leukemia
 vs peripheral T-cell lymphoma
 acute lymphoblastic leukemia (ALL), 190
 and problems with sheep E-rosette assays, 3
 in tissue sections, 6
 T_H lymphocytes, enzyme histochemistry and, 5
 t(1;19), acute lymphoblastic leukemia (ALL) and, 179
 t(12;21), acute lymphoblastic leukemia (ALL) and, 179
 t(9;22), acute lymphoblastic leukemia (ALL) and, 179–180
 Tandem fluorochromes, 24
 T-cell precursors
 acute lymphoblastic leukemia (ALL) and, 175–178
 immunophenotypic aberrancies in, 186–187, 189
 precursor T-lymphoblastic lymphoma/leukemia vs
 peripheral T-cell lymphoma, 186, 190
 T-cell receptor V β repertoire analysis in CD4/CD8 T-cell
 subsets, primary immunodeficiency disease and,
 225–227, 229
 Test pricing, and implementation of service, 102–103
 Test volume, and implementation of flow cytometry service,
 100
 Tetanus, multiplex bead array assays (MBAAs) and, 111
 Thalassemias, adult fetal hemoglobin (HbF) and, 296–298
 Thomas, E. Donnell, 321
 Thrombocytopenia
 ALL diagnosis and, 180–181
 RBC/PMS/platelet assays and, 295
 Wiscott-Aldrich syndrome (WAS) and, 232
 Thymocytes
 abnormalities in precursor T-cell ALL, 186–187
 maturation in thymoma of, 186–187
 Thymoma, precursor T-lymphoblastic lymphoma/leukemia
 vs, 185–188
 Tissue, T/B lymphocytes in, 6
- Training
 and implementation of flow cytometry service, 101
 QA and, 92
 Transplantation. *See also* Allogeneic transplantation
 allogeneic, 322
 autologous, 321–322
 erythropoietic activity evaluation and, 300
 HPSC allogeneic transplants, 322
 HPSC autologous transplants, 321–322
 Trastuzumab, 347
 Triage, hematolymphoid neoplasia analysis and, 121–122
 Trial Assigning Individualized Options for Treatment
 (TAILORx), 346
 Trypanosoma infections, 301
 Tumor necrosis factor alpha (TNF α)
 and antigen changes in hematopoietic cell differentiation,
 40
 dendritic cell generation and, 42
- Umbilical cord blood transplant, 322
 Undifferentiated acute leukemia, 203–207
 United Kingdom National External Quality Assessment
 Scheme (UK NEQAS), 263–264, 266
 Unrelated donor transplant, 322
 US-Canadian Consensus Conference, 74
- Validation protocol
 accuracy and, 77–79
 analytic measurement range (AMR)/clinical reportable
 range (CRR) and, 80
 analytic sensitivity and, 80
 of antibody panel configuration, 81–82
 documentation and, 82
 precision and, 79–80
 reference interval and, 81
 sample handling and, 81
 stability and, 80–81
 Validation/verification, 96
 as component of quality assurance (QA), 73
 Van der Waals forces antibody-antigen interactions, 6
 Vascular prostheses, platelet function abnormalities and, 311
 Verification, 96
 Verity, 67
 Viability assessment
 CD34+ measurement and, 330–331
 specimen quality/quantity and, 90–91
 Vitamin deficiencies, erythropoietic activity evaluation and,
 299
 Volumetric capillary cytometry, 22–23
 clinical flow cytometry and, 23
- WAS protein (WASP), 232
 West Nile virus, multiplex bead array assays (MBAAs) and,
 111
 Whole blood lysis preparation of leukocytes, 29
 Whole blood preparation, hematolymphoid neoplasia
 analysis and, 120
 Winlist, 64, 67
 Wiscott-Aldrich syndrome (WAS), primary
 immunodeficiency disease and, 232–234
 Workshops on Human Leukocyte Differentiation Antigens,
 35–36
 World Health Organization (WHO)
 cluster designation (CD) terminology and, 9
 hematolymphoid neoplasias and, 121
 HIV/AIDS numbers, 260
 tumor cell heterogeneity in prostate cancer, 348
- XLA: BTK, primary immunodeficiency disease and, 231
 X-linked HIGM syndrome (CD40 ligand measurement),
 primary immunodeficiency disease and, 232, 235–238
 X-linked SCID: γ C/CD132, primary immunodeficiency
 disease and, 231
 xMAP software, 56
 XML. *See* Extensible Markup Language (XML)